Provided by Tiger Trade Technology Pte. Ltd.

Fractional Shares

2,045.67
+9.480.47%
Number of Gainers:677
Number of Losers:323
Number of Flat:20
PE:- -
High:2,051.98
Open:2,036.29
Low:2,036.19
Close:2,036.19
Volume:5.13B
Turnover:652.17B
Market Cap:97.70T
Float Cap:91.44T

Loading ...

Abbott announces U.S. commercial launch of SimpleScreen CRC

TIPRANKS
·
Sep 30

Dow to Showcase Pharmaceutical Innovations at CPHI Milan 2026

Reuters
·
Sep 30

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Sep 30

Theriva Biologics Says Nature Medicine Publishes Virage Phase 2b Results for VCN-01 in Metastatic Pancreatic Cancer

Reuters
·
Sep 30

Jabil Posts Strong Earnings. the Stock Falls Anyway.

Dow Jones
·
Sep 30

Integer Says U.S. Antitrust Waiting Period Ends Early for KKR Deal at USD 127 a Share

Reuters
·
Sep 30

Trio Petroleum Acquires 24 Lloydminster Oil Wells for CDN$ 800,000, Transfers Water Disposal Asset to Marlin Resources

Reuters
·
Sep 30

DarkIris Sets up U.S. Subsidiary to Expand North America Operations

Reuters
·
Sep 30

Airbnb Adds AI Search, More Social Features - TechCrunch

Reuters
·
Sep 30

IBM Study Shows 62% of CFOs Take on Enterprise AI Strategy Leadership

Reuters
·
Sep 30

Bank of America Private Bank Study Shows 89% of Wealthy Americans Give to Charity in 2025

Reuters
·
Sep 30

SEI Names Connall McGuckian Managing Director, Head of Singapore

Reuters
·
Sep 30

Rocket Doctor AI CEO Essam Hamza to Present at NIBA Investment Conference

Reuters
·
Sep 30

US Equity Futures Mostly Flat Pre-Bell as Traders Await Key Inflation Report

MT Newswires Live
·
Sep 30

Verrica Says Pooled Phase 3 Analysis Shows Ycanth Clears Molluscum About 4x Faster than Vehicle

Reuters
·
Sep 30

Eli Lilly - 77% of Ebglyss Patients Reported Satisfaction with Hand Clearance at Week 16

THOMSON REUTERS
·
Sep 30

Eli Lilly - Ebglyss Monotherapy Meets Primary and Secondary Endpoints at Week 16 in Phase 3B Adtouch Study

THOMSON REUTERS
·
Sep 30

New Phase 3B Data Show Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Significant and Rapid Improvements in Skin Clearance, Itch, Pain, and Patient Satisfaction in People with Moderate-to-Severe Hand and Foot Atopic Dermatitis

THOMSON REUTERS
·
Sep 30

Eli Lilly - Treatment-Emergent Adverse Events in 41.8% Ebglyss Patients, 39.6% Placebo, All Mild or Moderate

THOMSON REUTERS
·
Sep 30

Eli Lilly - Submits Ebglyss Adtouch Data to FDA and Plans Global Regulatory Submissions for Label Update

THOMSON REUTERS
·
Sep 30